Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.

Prasad GVR, Beckley J, Mathur M, Gunasekaran M, Nash MM, Rapi L, Huang M, Zaltzman JS.

BMC Infect Dis. 2019 Apr 5;19(1):311. doi: 10.1186/s12879-019-3944-0.

2.

Is There a Role for mTOR Inhibitors in Renal Transplantation?

Zaltzman JS.

Transplantation. 2017 Feb;101(2):228-229. doi: 10.1097/TP.0000000000001541. No abstract available.

PMID:
27779576
3.

The Impact of Total Gastrectomy on Pharmacokinetics in Kidney Transplant Immunosuppressive Drug Regimes: A Case Study.

Chen L, Liberatore L, Chin T, Walker S, Fanous H, Nash MM, Rapi L, Huckle J, Zaltzman JS, Prasad GVR.

Transplantation. 2017 Sep;101(9):2213-2217. doi: 10.1097/TP.0000000000001507.

PMID:
27748705
4.

Reduction in new-onset diabetes mellitus after renal transplant with erythropoietin-stimulating agents: a retrospective cohort study.

Montada-Atin T, Choi D, Woo M, Retnakaran R, Huang M, Prasad GV, Zaltzman JS.

Can J Kidney Health Dis. 2016 Apr 26;3:23. doi: 10.1186/s40697-016-0114-9. eCollection 2016.

5.

Commercial kidney transplantation is an important risk factor in long-term kidney allograft survival.

Prasad GVR, Ananth S, Palepu S, Huang M, Nash MM, Zaltzman JS.

Kidney Int. 2016 May;89(5):1119-1124. doi: 10.1016/j.kint.2015.12.047. Epub 2016 Mar 9.

PMID:
27083285
6.

Public solicitation for organ donors: a time for direction in Canada.

Elman A, Wright L, Zaltzman JS.

CMAJ. 2016 Apr 19;188(7):487-488. doi: 10.1503/cmaj.150964. Epub 2016 Feb 29. No abstract available.

7.

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients.

Zaltzman AS, Glick LA, Zaltzman JS, Nash M, Huang M, Prasad GV.

Transplant Res. 2016 Jan 28;5:2. doi: 10.1186/s13737-016-0031-6. eCollection 2016.

8.

Lithium-Induced Minimal Change Disease and Acute Kidney Injury.

Tandon P, Wong N, Zaltzman JS.

N Am J Med Sci. 2015 Jul;7(7):328-31. doi: 10.4103/1947-2714.161252.

9.

IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.

Heon EK, Wulan H, Macdonald LP, Malek AO, Braunstein GH, Eaves CG, Schattner MD, Allen PM, Alexander MO, Hawkins CA, McGovern DW, Freeman RL, Amir EP, Huse JD, Zaltzman JS, Kauff NP, Meyers PG, Gleason MH, Overholtzer MG, Wiseman SS, Streutker CD, Asa SW, McAlindon TP, Newcomb PO, Sorensen PM, Press OA.

Biochem Biophys Res Commun. 2015 Aug 14;464(1):360-6. doi: 10.1016/j.bbrc.2015.06.162. Epub 2015 Jun 30.

PMID:
26141233
10.

A clinical and pathological variant of acute transplant glomerulopathy.

Molnar MZ, Prasad GV, Yuen DA, Jothy S, Zaltzman JS.

Case Rep Pathol. 2014;2014:961987. doi: 10.1155/2014/961987. Epub 2014 Sep 11.

11.

Metabolic syndrome definitions and components in predicting major adverse cardiovascular events after kidney transplantation.

Prasad GV, Huang M, Silver SA, Al-Lawati AI, Rapi L, Nash MM, Zaltzman JS.

Transpl Int. 2015 Jan;28(1):79-88. doi: 10.1111/tri.12450. Epub 2014 Oct 7.

12.

A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers.

Zaltzman JS, Lai V, Schulz MZ, Moon KH, Cherney DZ.

Transpl Int. 2014 Dec;27(12):1294-302. doi: 10.1111/tri.12435. Epub 2014 Sep 29.

13.

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity.

Glick L, Shamy F, Nash M, Sokwala A, Malavade T, Prasad GR, Zaltzman JS.

Transplant Res. 2014 Mar 10;3(1):7. doi: 10.1186/2047-1440-3-7.

14.

A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study.

Fanous H, Zheng R, Campbell C, Huang M, Nash MM, Rapi L, Zaltzman JS, Prasad GV.

Clin Kidney J. 2013 Feb;6(1):45-49. Epub 2012 Jan 1.

15.

A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients.

Cole EH, Prasad GV, Cardella CJ, Kim JS, Tinckam KJ, Cattran DC, Schiff JR, Landsberg DN, Zaltzman JS, Gill JS.

Transplant Res. 2013 Jan 12;2(1):1. doi: 10.1186/2047-1440-2-1.

16.

Kidney transplant tourism: cases from Canada.

Wright L, Zaltzman JS, Gill J, Prasad GV.

Med Health Care Philos. 2013 Nov;16(4):921-4. doi: 10.1007/s11019-012-9450-4. Review.

PMID:
23192569
18.

South Asian ethnicity as a risk factor for major adverse cardiovascular events after renal transplantation.

Prasad GV, Vangala SK, Silver SA, Wong SC, Huang M, Rapi L, Nash MM, Zaltzman JS.

Clin J Am Soc Nephrol. 2011 Jan;6(1):204-11. doi: 10.2215/CJN.03100410. Epub 2010 Sep 30.

19.

Reply.

Gupta AK, Jothy S, Somerville P, Zaltzman JS.

NDT Plus. 2010 Jun;3(3):326-327. doi: 10.1093/ndtplus/sfq040. Epub 2010 Feb 28. No abstract available.

20.

Hypocomplementaemic immune complex tubulointerstitial nephritis.

Gupta A, Jothy S, Somerville P, Zaltzman JS.

NDT Plus. 2010 Feb;3(1):78-80. doi: 10.1093/ndtplus/sfp141. Epub 2009 Oct 7.

21.

Microalbuminuria post-renal transplantation: relation to cardiovascular risk factors and C-reactive protein.

Prasad GV, Bandukwala F, Huang M, Zaltzman JS.

Clin Transplant. 2009 Jun-Jul;23(3):313-20.

PMID:
19537299
22.

Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk.

Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV.

Am J Cardiol. 2009 Mar 15;103(6):867-71. doi: 10.1016/j.amjcard.2008.11.042. Epub 2009 Jan 24.

PMID:
19268747
23.

Pre-transplantation glucose testing for predicting new-onset diabetes mellitus after renal transplantation.

Ramesh Prasad GV, Huang M, Bandukwala F, Nash MM, Rapi L, Montada-Atin T, Meliton G, Zaltzman JS.

Clin Nephrol. 2009 Feb;71(2):140-6.

PMID:
19203506
24.

Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.

Jevnikar A, Arlen D, Barrett B, Boucher A, Cardella C, Cockfield SM, Rush D, Paraskevas S, Shapiro J, Shoker A, Yilmaz S, Zaltzman JS, Kiberd B.

Transplantation. 2008 Oct 15;86(7):953-60. doi: 10.1097/TP.0b013e318186dd0c.

PMID:
18852662
25.

Seasonal variation of serum lipid levels in stable renal transplant recipients.

Wong BM, Huang M, Zaltzman JS, Prasad GV.

Nephron Clin Pract. 2007;105(3):c126-31. Epub 2007 Jan 16.

PMID:
17228172
26.

Mycophenolate mofetil and C-reactive protein in renal transplant recipients.

Wong BM, Huang M, Zaltzman JS, Prasad GV.

Transplantation. 2007 Jan 15;83(1):48-53.

PMID:
17220790
27.

Outcomes of commercial renal transplantation: a Canadian experience.

Prasad GV, Shukla A, Huang M, D'A Honey RJ, Zaltzman JS.

Transplantation. 2006 Nov 15;82(9):1130-5.

PMID:
17102761
28.

A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.

Kim SJ, Prasad GV, Huang M, Nash MM, Famure O, Park J, Thenganatt MA, Chowdhury N, Cole EH, Fenton SS, Cattran DC, Zaltzman JS, Cardella CJ.

Transplantation. 2006 Oct 15;82(7):924-30.

PMID:
17038908
29.

Kidney transplantation in Canada: unequal access.

Zaltzman JS.

CMAJ. 2006 Aug 29;175(5):489-90. No abstract available.

30.

The role of dietary cations in the blood pressure of renal transplant recipients.

Ramesh Prasad GV, Huang M, Nash MM, Zaltzman JS.

Clin Transplant. 2006 Jan-Feb;20(1):37-42.

PMID:
16556151
31.

Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus.

Zaltzman JS, Prasad R, Chun K, Jothy S.

Nephrol Dial Transplant. 2005 Aug;20(8):1748-51. Epub 2005 May 26. No abstract available.

PMID:
15919698
32.

Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression.

Prasad GV, Huang M, Nash MM, Zaltzman JS.

Transplant Proc. 2005 May;37(4):1896-7.

PMID:
15919496
33.

Renal transplantation among South Asians: a North American perspective.

Prasad GV, Zaltzman JS, Huang M.

Transplantation. 2005 Apr 15;79(7):855. No abstract available.

PMID:
15818334
34.

Death with graft function in elderly patients after cadaveric renal transplantation: effect of waiting time.

Noseworthy PA, Huang M, Zaltzman JS, Ramesh Prasad GV.

Transplant Proc. 2004 Dec;36(10):2985-7.

PMID:
15686676
35.

A prospective 3-yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high risk renal allograft recipients.

Zaltzman JS, Boucher A, Busque S, Halloran PF, Landsberg DN, McAlister VC, Russell D, Shoker A, Shapiro J, Tchervenkov JI, Ferguson R.

Clin Transplant. 2005 Feb;19(1):26-32.

PMID:
15659130
36.

Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins).

Prasad GV, Kim SJ, Huang M, Nash MM, Zaltzman JS, Fenton SS, Cattran DC, Cole EH, Cardella CJ.

Am J Transplant. 2004 Nov;4(11):1897-903.

37.

Handwashing precautions taken by renal transplant recipients for severe acute respiratory syndrome.

Prasad GV, Nash MM, Zaltzman JS.

Transplantation. 2004 Jun 27;77(12):1917. No abstract available.

PMID:
15223923
38.

A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.

Prasad GV, Nash MM, McFarlane PA, Zaltzman JS.

Nephron Clin Pract. 2004;97(2):c35-40.

PMID:
15218328
39.

The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy.

Zaltzman JS, Nash M, Chiu R, Prasad R.

Nephrol Dial Transplant. 2004 Apr;19(4):940-4.

PMID:
15031353
40.

Recurrence of type III membranoproliferative glomerulonephritis after renal transplantation.

Ramesh Prasad GV, Shamy F, Zaltzman JS.

Clin Nephrol. 2004 Jan;61(1):80-1. No abstract available.

PMID:
14964464
41.

Renin-angiotensin system blockade in biopsy-proven allograft nephropathy.

Zaltzman JS, Nash M, Chiu R, Prasad GV.

Transplant Proc. 2003 Nov;35(7):2415-7.

PMID:
14611974
42.

Statin use and bone mineral density in renal transplant recipients.

Prasad GV, Chiu R, Nash MM, Zaltzman JS.

Am J Transplant. 2003 Oct;3(10):1320-1. No abstract available.

43.

Renal transplant recipient attitudes toward steroid use and steroid withdrawal.

Prasad GV, Nash MM, McFarlane PA, Zaltzman JS.

Clin Transplant. 2003 Apr;17(2):135-9.

PMID:
12709080
44.

A prospective study of the physician effect on blood pressure in renal-transplant recipients.

Prasad GV, Nash MM, Zaltzman JS.

Nephrol Dial Transplant. 2003 May;18(5):996-1000.

PMID:
12686677
45.

Kidney transplantation in the elderly: a decision analysis.

Jassal SV, Krahn MD, Naglie G, Zaltzman JS, Roscoe JM, Cole EH, Redelmeier DA.

J Am Soc Nephrol. 2003 Jan;14(1):187-96.

46.

Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients.

Prasad GV, Ahmed A, Nash MM, Zaltzman JS.

Kidney Int. 2003 Jan;63(1):360-4.

47.

Seasonal variation in outpatient blood pressure in stable renal transplant recipients.

Prasad GV, Nash MM, Zaltzman JS.

Transplantation. 2001 Dec 15;72(11):1792-4.

PMID:
11740390
48.

Mycophenolate mofetil causing deep venous thrombosis in a renal transplant patient with factor V Leiden.

Cherney DZ, Zaltzman JS.

Nephrol Dial Transplant. 2001 Aug;16(8):1702-4. No abstract available.

PMID:
11477179
49.

ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.

Stigant CE, Cohen J, Vivera M, Zaltzman JS.

Am J Kidney Dis. 2000 Jan;35(1):58-63.

PMID:
10620545
50.

Development of focal segmental glomerulosclerosis in the renal allograft of a patient with lupus.

Kim JS, Sugar L, Zaltzman JS.

Am J Kidney Dis. 1999 Sep;34(3):e13.

PMID:
10471755

Supplemental Content

Loading ...
Support Center